Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15631292 | 0.90 | GABRA1 (0.61) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL25505919 | 0.86 | GABRA1 (0.47) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL22251623 | 0.84 | HSD17B10 (0.46) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL31075865 | 0.84 | GABRA1 (0.45) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL7916578 | 0.84 | ADRB2 (0.46) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL27439609 | 0.78 | GABRA1 (0.54) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL8134770 | 0.78 | CES2 (0.41) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL4471799 | 0.78 | ADRB2 (0.39) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL1597063 | 0.78 | CYP1A2 (0.48) | ADRB2ADRB1ADRB3RPS6KA3CYP1A2 | |
| SCHEMBL6346880 | 0.78 | GABRA1 (0.73) | GABRA1GABRB2ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023118576-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | IMMUNIC AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC | 2007-11-22 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | GABRA1 3590/4885GABRB2 3049/4885ADRB2 3963/4885 |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | PTGIR, PTGIS, PTGS1 | GABRA1 360/4885GABRB2 466/4885ADRB2 160/4885 |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SMN1; SMN2, TDP2, TDP1 | GABRA1 1342/4885GABRB2 544/4885ADRB2 120/4885 |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | PTGIS, PTGIR, CYP11B2 | GABRA1 983/4885GABRB2 716/4885ADRB2 118/4885 |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | GABRA1 3193/4885GABRB2 2318/4885ADRB2 3558/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GABRA1 4438/4885GABRB2 3778/4885ADRB2 2455/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | GABRA1 1375/4885GABRB2 1112/4885ADRB2 546/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | GABRA1 3548/4885GABRB2 2981/4885ADRB2 1359/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | GABRA1 2585/4885GABRB2 2130/4885ADRB2 1116/4885 |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ABCB1, CYP11B2, SLC10A1 | GABRA1 1491/4885GABRB2 1641/4885ADRB2 441/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | GABRA1 164/4885GABRB2 123/4885ADRB2 2/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | GABRA1 1734/4885GABRB2 2552/4885ADRB2 3819/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | GABRA1 3345/4885GABRB2 2539/4885ADRB2 4303/4885 |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, TDP1 | GABRA1 1342/4885GABRB2 544/4885ADRB2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.